Followers | 43 |
Posts | 4265 |
Boards Moderated | 0 |
Alias Born | 07/14/2010 |
Thursday, July 15, 2021 3:20:43 PM
$0.00 revenue per share and burning over $22,000,000 million on the regular
Profitability
Profit Margin 0.00%
Operating Margin (ttm) -56,493.91%...........
Management Effectiveness
Return on Assets (ttm) -38.31%
Return on Equity (ttm) -71.91%
Income Statement
Revenue (ttm) 28.15k
Revenue Per Share (ttm) 0.00
Quarterly Revenue Growth (yoy) 1.50%
Gross Profit (ttm) -352.92k
EBITDA -15.88M
Net Income Avi to Common (ttm) -16.38M
Diluted EPS (ttm) -0.6600
Cash Flow Statement
Operating Cash Flow (ttm) -14.18M
Levered Free Cash Flow (ttm) -8.64M
Recent ATHE News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/23/2024 12:00:19 PM
- Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders® • GlobeNewswire Inc. • 09/23/2024 11:35:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/29/2024 10:07:27 AM
- Appendix 4C – Q4 FY24 Quarterly Cash Flow Report • GlobeNewswire Inc. • 07/31/2024 11:35:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/31/2024 10:23:35 AM
- Alterity Therapeutics to Present at MST Financial Webinar • GlobeNewswire Inc. • 07/24/2024 11:35:00 AM
- Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy • GlobeNewswire Inc. • 07/17/2024 11:35:00 AM
- Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy • GlobeNewswire Inc. • 07/17/2024 11:25:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/13/2024 12:28:27 PM
- Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar • GlobeNewswire Inc. • 06/12/2024 11:22:16 PM
- Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study • GlobeNewswire Inc. • 05/29/2024 11:21:24 PM
- Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review • GlobeNewswire Inc. • 05/08/2024 11:25:00 AM
- Appendix 4C – Q3 FY24 Quarterly Cash Flow Report • GlobeNewswire Inc. • 04/30/2024 11:25:00 AM
- Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia • GlobeNewswire Inc. • 04/29/2024 11:25:00 AM
- Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:25:00 AM
- Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 • GlobeNewswire Inc. • 04/10/2024 11:25:00 AM
- Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund • GlobeNewswire Inc. • 03/26/2024 02:25:00 PM
- Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting • GlobeNewswire Inc. • 02/20/2024 03:25:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/15/2024 10:29:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/15/2024 10:28:37 PM
- Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review • GlobeNewswire Inc. • 02/06/2024 12:25:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 01:00:15 PM
- Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week • GlobeNewswire Inc. • 01/29/2024 12:24:00 PM
- Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones • GlobeNewswire Inc. • 01/22/2024 12:25:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/22/2024 11:12:21 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM